Working… Menu

Trial of Ixabepilone in Patients With HER-2 Negative Metastatic Breast Cancer (HIT) (HIT)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00790894
Recruitment Status : Terminated (The low accrual rate of the study (25% of the expected accrual rate))
First Posted : November 14, 2008
Last Update Posted : May 18, 2011
Information provided by:
Hellenic Cooperative Oncology Group

Tracking Information
First Submitted Date  ICMJE November 13, 2008
First Posted Date  ICMJE November 14, 2008
Last Update Posted Date May 18, 2011
Study Start Date  ICMJE November 2008
Actual Primary Completion Date April 2011   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: November 13, 2008)
The primary endpoint of the study is the best Overall Response (OR). [ Time Frame: At 6, 12 and 24 weeks ]
Original Primary Outcome Measures  ICMJE Same as current
Change History
Current Secondary Outcome Measures  ICMJE
 (submitted: November 13, 2008)
  • Efficacy endpoints: time to response, PFS, TTF, duration of response [ Time Frame: Duration of the study ]
  • OS Toxicity endpoints: incidence of hematological and non-hematological toxicities [ Time Frame: Duration of the study ]
  • Translational endpoints [ Time Frame: Duration of the study ]
Original Secondary Outcome Measures  ICMJE Same as current
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
Descriptive Information
Brief Title  ICMJE Trial of Ixabepilone in Patients With HER-2 Negative Metastatic Breast Cancer (HIT)
Official Title  ICMJE Phase II Randomized Trial of Ixabepilone Administered Weekly or Every Three Weeks in Patients With HER-2 Negative Metastatic Breast Cancer Previously Treated With Chemotherapy in the Neo-adjuvant or Adjuvant Setting
Brief Summary This is a Phase II Randomized, Open Label, Non-comparative Trial (Parallel Assignment and Efficacy Study) for patients with HER-2 Negative Metastatic Breast Cancer Previously Treated With chemotherapy in the Neo-Adjuvant or Adjuvant Setting.Patients will be randomized to receive Ixabepilone either every three weeks, or weekly for three weeks followed by one week off. Patients will be treated until consent withdrawal, intolerable toxicity or documented disease progression
Detailed Description Patients with measurable metastatic breast cancer that have been treated in the adjuvant or neo-adjuvant setting with chemotherapy will be considered for this study. Subjects must not have received cytotoxic chemotherapy for locally recurrent/metastatic disease. Patients who fulfil the eligibility criteria, and have signed inform consent for the trial will be centrally randomized by electronic means to one of two ixabepilone treatment arms. Stratification factors will include: time to recurrence from adjuvant treatment, calculated from the date of the last dose of adjuvant treatment to the date of relapse (≤ 1 year vs. > 1 year); and previous chemotherapy with taxane regimen in the neo-adjuvant or adjuvant setting (yes vs. no). Randomization will be balanced by site.Treatment Protocol· Arm A [standard once every three weeks schedule]:Ixabepilone [BMS-247550] will be administered on Day 1 (D1) every three weeks as a 3-hour infusion at a dose of 40 mg/m2. · Arm B [weekly schedule]:Ixabepilone [BMS-247550] will be administered weekly for three weeks as a 3-hour infusion at a dose of 20 mg/m2, followed by one week-off.Treatment can be continued until consent withdrawal by the patient, intolerable toxicity or documented disease progression.
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 2
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Condition  ICMJE Metastatic Breast Cancer
Intervention  ICMJE
  • Drug: ixabepilone
    Arm A: ixabepilone will be given at a dose of 40 mg/m2 as a 3-hour intravenous infusion on Day 1 in a 21 days cycle.
  • Drug: ixabepilone
    Arm B: ixabepilone will be given at a dose of 20 mg/m2 as a 3-hour intravenous infusion on Days 1, 8 and 15, then 1 week off in a 28-days cycle.
Study Arms  ICMJE
  • Active Comparator: 1
    Intervention: Drug: ixabepilone
  • Experimental: 2
    Intervention: Drug: ixabepilone
Publications * Fountzilas G, Kotoula V, Pectasides D, Kouvatseas G, Timotheadou E, Bobos M, Mavropoulou X, Papadimitriou C, Vrettou E, Raptou G, Koutras A, Razis E, Bafaloukos D, Samantas E, Pentheroudakis G, Skarlos DV. Ixabepilone administered weekly or every three weeks in HER2-negative metastatic breast cancer patients; a randomized non-comparative phase II trial. PLoS One. 2013 Jul 23;8(7):e69256. doi: 10.1371/journal.pone.0069256. Print 2013.

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
Recruitment Information
Recruitment Status  ICMJE Terminated
Actual Enrollment  ICMJE
 (submitted: May 17, 2011)
Original Estimated Enrollment  ICMJE
 (submitted: November 13, 2008)
Actual Study Completion Date  ICMJE May 2011
Actual Primary Completion Date April 2011   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • Written informed consent
  • Female patients aged 18 to 75 years inclusive
  • Prior chemotherapy in the adjuvant or neo-adjuvant setting
  • Diagnosis of HER-2 negative (HER-2 <2+ by immunohistochemistry and/or FISH negative) metastatic breast adenocarcinoma confirmed by the pathology department of the enrolling institution
  • Eastern Cooperative Oncology Group performance status of 0 or 1
  • Life expectancy of at least 12 weeks
  • Measurable disease by the Response Criteria in Solid Tumors (RECIST) method
  • Laboratory values within the specified ranges within 1 week of study enrolment:
  • Absolute neutrophil count of ≥ 1.5 x 109/L
  • Thrombocyte count of ≥ 100 x 109/L
  • Subjects must not have received cytotoxic chemotherapy for locally recurrent/metastatic disease
  • Prior hormonal therapy for locally recurrent or metastatic disease allowed
  • AST and ALT ≤ 2.5 x ULN
  • Bilirubin ≤ 1.5 x ULN
  • Recovery from prior palliative radiotherapy for bone metastases

Exclusion Criteria:

  • Because of concerns that ixabepilone metabolism may be inhibited by potent cytochrome P450 3A4 inhibitors, patients must not receive the following medications, up to 72 hours prior to initiation of study therapy and until they come off treatment with ixabepilone: amprenavir, delavirdine, voriconazole, erythromycin, cyclosporine, troleandomycin, terfenadine, ketoconazole, nelfinavir, and ritonavir
  • Patients with CTC grade 2 or greater neuropathy at baseline
  • Patients with any history or evidence of brain an/or leptomenigneal metastasis
  • Patients with clinically significant cardiac disease (e.g. unstable angina, congestive heart failure, myocardial infarction) within 6 months from study entry
  • Psychiatric disorders or other conditions rendering the subject incapable of complying with the requirements of the protocol
  • Any concurrent active malignancy other than non-melanoma skin cancer or in situ carcinoma of the cervix (subjects with a history of previous malignancies but without evidence of disease for 5 years will be allowed to enter the trial)
  • Prior severe HSR to agents containing Cremophor EL
  • Women of childbearing potential (WOCBP) who are unwilling or unable to use an adequate method of contraception to avoid pregnancy throughout the study and for up to 12 weeks from the last dose of ixabepilone, in such a manner that the risk of pregnancy is minimized WOCBP include: any female who has experienced menarche and who has not undergone successful surgical sterilization (hysterectomy, bilateral tubal ligation or bilateral oophorectomy) or is not postmenopausal (defined as amenorrhea ≥ 12 consecutive months; women on hormone replacement therapy with documented FSH level > 35mIU/mL. Even women who are practising abstinence or whom their partner is sterile (e.g. vasectomy) should be considered of childbearing potential.
  • Women who are pregnant or breastfeeding
  • Women with a positive pregnancy test on enrolment or prior to study therapy
  • No other concomitant chemotherapy, endocrine therapy, immunotherapy, radiation therapy (except for palliative radiotherapy for bone metastases) or investigational treatments are allowed during subject's participation in the study
Sex/Gender  ICMJE
Sexes Eligible for Study: Female
Ages  ICMJE 18 Years to 75 Years   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE Greece
Removed Location Countries  
Administrative Information
NCT Number  ICMJE NCT00790894
Other Study ID Numbers  ICMJE HE 11A08
Has Data Monitoring Committee No
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE Not Provided
Responsible Party G. Fountzilas/President, Hellenic Cooperative Oncology Group
Study Sponsor  ICMJE Hellenic Cooperative Oncology Group
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Principal Investigator: George Fountzilas Papageorgiou General Hospital
PRS Account Hellenic Cooperative Oncology Group
Verification Date May 2011

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP